Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, Jun 10 () Pharma major Cipla on Wednesday said it will acquire 21.85 per cent stake in GoApptiv on a fully-diluted basis in two phases. The cost of acquisition is Rs 9 crore (Rs 5.80 crore in the first stage and Rs 3.20 crore in the second stage), it said in a regulatory filing. In the first stage, subscription of 15,392 compulsorily convertible preference shares and purchase of 6,927 equity shares is expected to be closed within 30 days from the execution date, subject to certain conditions precedent,. In the second stage, "subscription of 12,314 compulsorily convertible preference shares is expected to close by October 31, subject to certain conditions precedent," it added. GoApptiv offers digital solutions for integrated brand sales management, digital marketing and channel engagement for pharmaceutical companies. It also provides digital solutions for customer relationship management, patient support and healthcare data analytics. Through an equity investment, representing 21.85 per cent stake in GoApptiv, the drug firm will strengthen its partnership with the firm so as to enable widening reach of its key brands in the tier-3 plus towns, Cipla said. The shares of Cipla were trading at Rs 648.20 apiece on BSE in morning trade, up 1.30 per cent from their previous close. SID SID ANS ANS

Cipla to acquire 21.85 pc stake in GoApptiv

<ul><li>The SGX Nifty was trading 0.04% lower at 7:51 am, indicating a flat start for Nifty50. </li><li>Here’s a list of stocks to watch for in trade today. </li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider. </a></li></ul>Amidst mixed cues from the global markets, the Indian stock market is likely to open with a negative bias on Tuesday. The SGX Nifty was trading 0.04% lower at 7:51 am, indicating a flat start for Nifty50. Whereas, the US stocks ended the Monday higher as the tech stocks rallied amid the stimulus hopes. The Dow Jones Industrial Average closed 250.62 points higher; whereas the S&amp;P 500 was up over 1.6%. These are the stocks to watch out for during the trading session on October 13: Lakshmi Vilas Bank The private lender Lakshmi Vilas Bank (LVB) informed stock-exchanges that its board would meet on October 15 to consider a rights issue to raise capital up to ₹1,000 crore. The shares of Lakshmi Vilas Bank closed 5% lower yesterday. Reliance Industries The Mukesh-Ambani owned Reliance Jio became the first telecom company in India to cross 40 crore customers mark with the net addition of over 35 lakh subscribers in July, according to the telecom regulator TRAI data released on October 12. The shares of RIL closed 0.11% higher yesterday. Airtel and Vodafone The stocks of other telecom giants Airtel and Vodafone, will also remain in focus. As per the TRAI data, Vodafone Idea lost 3.7 million users, and Bharti Airtel added over 3.26 million wireless subscribers in July. The shares of Airtel and Vodafone closed nearly 3% lower yesterday. Infosys The IT giant Infosys has completed the acquisition of a US-based product design and development firm Kaleidoscope Innovation for about ₹308 crore. The company will also be posting its quarterly earnings tomorrow. The shares of Infosys closed 2.93% higher yesterday. SRF Limited The fluorochemicals, speciality chemicals manufacturing company SRF has set the floor price of its qualified institutional placement (QIP) at ₹4,168.73 per share. The shares of SRF Limited closed 2.67% higher yesterday. Shalby Multispeciality hospital chain Shalby reported a consolidated net profit of ₹24.5 crore in the second quarter ended September 30 compared to ₹12.9 crore year-on-year. However, the company’s overall revenue fell to ₹115.6 crore from ₹125.7 crore at the same time last year. The shares of Shalby closed 4% higher yesterday. Cipla The drug major Cipla said the company’s step-down associate firm Avenue Therapeutics Inc had received a complete response letter (CRL) from the US health regulator for its new drug application for intravenous tramadol. The letter stated that IV tramadol intended to treat patients in acute pain who require an opioid is not safe for the intended patient population. The shares of Cipla closed 1.81% higher yesterday. Wipro The tech giant Wipro is slated to announce its earnings for the second quarter ended September 30. The shares of Wipro closed 1.47% higher yesterday. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/johnson-johnson-just-paused-its-coronavirus-vaccine-trials-after-an-unexplained-illness-in-a-participant/articleshow/78630971.cms" data-type="tilCustomLink">Johnson &amp; Johnson just paused its coronavirus vaccine trials after an 'unexplained illness' in a participant</a> <a href="https://www.businessinsider.in/tech/news/the-iphone-12-could-be-apples-most-important-product-release-in-the-last-decade/articleshow/78627338.cms" data-type="tilCustomLink">The iPhone 12 could be Apple's most important product release in the past decade</a>

Top stocks to watch — RIL, Airtel, Vodafone-Idea, Infosys, Wipro, Shalby, Cipla, and others

<ul><li>The 30-share BSE index was trading 1% higher; while the Nifty50 was up 100 points at 10:05 am. </li><li>These were the top losers and gainers in the Nifty pack. </li><li>These are the top stocks that are buzzing in trade today.</li><li><a href="https://www.businessinsider.in/">Check out the latest news and updates on Business Insider.</a> </li></ul>Indian stock market index Sensex gained over 400 points on Friday, led by positive cues from global markets. The key sectoral indices were trading higher after the bank, auto, finance, metal, and pharma gained during the early trade hours. The 30-share BSE index was trading 1% higher; while the Nifty50 was up 100 points at 10:05 am. These were the top losers and gainers in the Nifty pack: <table style="border-width: initial; border-style: none;"></colgroup><tbody><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Gainers </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Top Nifty Losers </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Adani Ports </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Kotak Mahindra Bank </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">TCS </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HDFC Limited </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">HCL Tech </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">- </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Eicher Motors </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">- </td></tr><tr><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">IndusInd Bank </td><td style="border-left:solid #000000 0.9907650000000001pt;border-right:solid #000000 0.9907650000000001pt;border-bottom:solid #000000 0.9907650000000001pt;border-top:solid #000000 0.9907650000000001pt;vertical-align:bottom;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">- </td></tr></tbody></table>*as of September 25, 10:00 am TCS trades 3% higher The shares of tech giant TCS were trading 3% higher on Friday after the company said that the American women’s clothing retail chain Maurices had hired the company as its digital transformation partner. TCS will help Maurices build its greenfield IT ecosystem with the intent of optimising its 200 existing applications and software components within the next 17 months. Granules India gained 9% Granules India was trading 9% higher after <a href="https://www.moneycontrol.com/news/business/kkr-bain-capital-and-blackstone-in-race-for-majority-stake-in-granules-india-5881931.html">news reports</a> indicate that three global private equity players — KKR, Bain Capital and Blackstone— have shown preliminary interest in acquiring a controlling stake Granules India. Cipla opens 3% higher The shares of pharma giant Cipla surged 3% after the company received USFDA approval for a multiple sclerosis drug. The drug is used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Advanced Enzyme Technologies soar 7% Advanced Enzyme Technologies share price soared 7% after the foreign portfolio investor (FPI) bought nearly 4% stake in the agricultural products company via the open market. This came after Nalanda India Equity Fund on Thursday bought 3.75% stake. Tata Coffee and Tata Consumer leaps 4% The share price of Tata Coffee and Tata Consumer surged 4% after <a href="https://www.business-standard.com/article/companies/tata-consumer-products-plans-to-bid-for-coffee-day-s-vending-business-120092401736_1.html">media reports</a> surfaced that the consumer arm of Tata Group, Tata Consumer Products, is planning to bid for the vending machine business of Coffee Day Enterprises. The reports claim that the board of Tata Consumer had approved the proposal to explore an acquisition of the operation from Coffee Day. RIL gains nearly a percent The shares of Mukesh Ambani owned RIL were trading nearly a percent higher on Friday. The company’ telecom arm Jio has partnered AeroMobile to launch mobile services on 22 flights on international routes, with plans starting at ₹499 per day. The partner airlines include Virgin Atlantic, Alitalia, Swiss, Emirates, Etihad Airways, Euro Wings, Lufthansa, Malindo Air and Biman Bangladesh Airlines. Another<a href="https://www.business-standard.com/article/companies/ril-in-talks-to-buy-electronics-chain-in-south-deal-may-hit-rs-3-000-cr-120092401238_1.html"> news report</a> highlights that RIL’s retail arm, Reliance Retail is in race to acquire a south based consumer durables retail chain operator Electronics Mart India. Electronics Mart operates 60 stores in South India with 1,200 employees on its roll. SEE ALSO: <a href="https://www.businessinsider.in/india/news/bharat-bandh-farmer-unions-begin-their-nationwide-strike-delhi-police-on-high-alert/articleshow/78308504.cms" data-type="tilCustomLink">Bharat Bandh: Farmer unions begin their nationwide strike — Delhi Police on high alert</a> <a href="https://www.businessinsider.in/finance/banks/news/no-fresh-ibc-proceedings-till-december-says-centre/articleshow/78308167.cms" data-type="tilCustomLink">No fresh IBC proceedings till December, says Centre</a>

Top stock movers — RIL, Granules, TCS, Cipla, Advanced Enzyme Tech, Tata Consumer, and more

New Delhi, Feb 8 () Homegrown pharma firm Cipla on Saturday announced the acquisition of nutrition products portfolio from Wanbury Ltd. The company has acquired 4 brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in women's health portfolio. The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies, Cipla said in a regulatory filing. This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health, it said. Through this newly acquired portfolio, the company shall be catering to a wide range of patient's needs including nutritional deficiencies, bone health and sexual health, it said. The above molecules previously commercialized by Wanbury have a market size of Rs 3,100 crore in India with sales value of Rs 59.6 crore. DP DP ANUANU

Cipla acquires 4 nutrition brands from Wanbury

<ul><li><keyword id="11451125" type="UNKNOWN" weightage="100" keywordseo="gozoop-group">Gozoop Group</keyword> has acquired its fifth agency, <keyword id="11451121" type="UNKNOWN" weightage="20" keywordseo="stratton-communications">Stratton Communications</keyword>.</li><li>Stratton will be rebranded as Sm(all) and will operate independently within the Gozoop Group.</li><li>We caught up with Ahmed Aftab Naqvi, CEO &amp; Co-Founder, Gozoop Group, Rohan Bhansali, Co-Founder &amp; Director, Gozoop Group and Siddhanth Valecha, CEO, Sm(all) to find out more about the alliance and Gozoop Group’s vision ahead.</li></ul>The Gozoop Group has acquired Digital Agency Stratton Communications. This is Gozoop’s fifth acquisition. Before this, the group had acquired Red Digital in 2013, which is a part of the Dream11 Group, iThink in 2014, 56 Blue Lights in 2016 and Hat Media in 2018. After the acquisition, Stratton will be rebranded as Sm(all) and will focus on challenger brands under Gozoop’s umbrella. The agency aims at gaining recognition for its ability to use human insights to unlock authentic brand experiences that drive meaningful engagements primarily on short-form content platforms. With Siddhanth Valecha as the CEO of Sm(all), the agency will operate independently within the group and will report to the Gozoop Board. The group has already added clients such as Cipla, Regal Shoes, ExtraMile, Nasher Miles and Aster Labs in the last two months after the acquisition. Pre-pandemic, Stratton had earned Rs 2.5 crore in annual revenues and now, Sm(all) is only aiming to go bigger! We caught up with Ahmed Aftab Naqvi, CEO &amp; Co-Founder, Gozoop Group, Rohan Bhansali, Co-Founder &amp; Director, Gozoop Group and Siddhanth Valecha, CEO, Sm(all) to further understand what the acquisition means for the group, what it is like to form an alliance during a pandemic and vision ahead. Excerpts: <cmsannotation type="cmsannotation" annotationid="Q. Can you tell me a little bit about this acquisition? When did the talks begin?" text="Q. Can you tell me a little bit about this acquisition? When did the talks begin?">Q. Can you tell me a little bit about this acquisition? When did the talks begin?</cmsannotation> Rohan: We have been on the lookout for a mid-size agency since mid-2020. The vision we were working towards was to have a second full-service agency as part of Gozoop Group. We were introduced to Siddhanth in November 2020. Through Stratton, Siddhanth has helped build some strong challenger brands with bold marketing campaigns. Siddhanth is famous (or infamous as he would say) for the first pizza to be delivered by a drone in India. This campaign was done for a pizza brand that caught not only the attention of the media but also city authorities. We loved the boldness of it. We had shortlisted three agencies as part of our search for a second agency. Amongst them, we saw the best creative and value fit in Stratton. In Stratton, we found a player that thrives on taking risks to break the marketing clutter. The negotiations took a couple of months and we formalized the terms of the deal in February 2021. <cmsannotation type="cmsannotation" annotationid="Q. How will Stratton operate under Gozoop Group’s umbrella?" text="Q. How will Stratton operate under Gozoop Group’s umbrella?">Q. How will Stratton operate under Gozoop Group’s umbrella?</cmsannotation> Ahmed: Stratton will operate independently within the framework of defined values and business principles of Gozoop Group. It has been rebranded as Sm(all) to be more in line with its vision of building challenger brands. Sm(all) will have its own culture, which will be a derivative of Siddhanth’s leadership style. We feel that that’s a prerequisite for this venture to succeed. We don’t want it to lose its bold essence. In fact, we want to accentuate it. Siddhanth: Stratton as a company, in its true element, was what initially attracted Rohan and Ahmed’s attention. Additionally, for me, staying true to our core as Stratton was also of utmost importance. Therefore, what’s made this even more comforting or rather seamless is that all three of us widely agreed on keeping the essence of Stratton, now Sm(all), in sync with what I had initially envisioned it to be. We will be operating independently under the Gozoop Group. And I couldn’t be more excited. <cmsannotation type="cmsannotation" annotationid="Q. What kind of synergies will Gozoop share with Sm(all)?" text="Q. What kind of synergies will Gozoop share with Sm(all)?">Q. What kind of synergies will Gozoop share with Sm(all)?</cmsannotation> Rohan: At Gozoop, our ecosystem is set to best service brands such as Dell, Indian Hotels and Bisleri that are market leaders in their categories. Such brands obviously have different needs than challenger brands. With Sm(all), at a group level, now we can service such challenger brands that Gozoop earlier couldn’t due to non-compete as well as the size of business reasons. The corporate side of the business – HR, Finance, IT – will have further synergies. While these will be centralized to benefit from the Group’s strong systems, specific subsystems have been set to better suit Sm(all). <cmsannotation type="cmsannotation" annotationid="Q. How will the alliance help strengthen your overall offering?" text="Q. How will the alliance help strengthen your overall offering?">Q. How will the alliance help strengthen your overall offering?</cmsannotation> Ahmed: At a business level, we can monetize existing opportunities better as we can now service a wider array of brands. We earlier had to pass on these opportunities to other agencies. This will help revenue and bring down our overhead costs at a per employee level. As stated above, it will also lead to higher efficiencies in our horizontal functions such as HR, Finance, IT and PR. At an execution level, Sm(all) brings its own unique and bold style of brand development that will build creative repute at the Agency as well as Group level. Stratton has been well known in the industry for bold creative campaigns. Expect some firework campaigns from the den of Sm(all). Siddhanth: Gozoop is well known in the advertising industry for its culture and processes, therefore, collaborating in 3 major departments with a solid partner will only make things easier for us. It’ll help us focus on our key offerings of helping brands build a community and a narrative using our modern-day understanding and expertise. <cmsannotation type="cmsannotation" annotationid="Q. Who crafted the name of the agency Sm(all) and what was the idea behind it?" text="Q. Who crafted the name of the agency Sm(all) and what was the idea behind it?">Q. Who crafted the name of the agency Sm(all) and what was the idea behind it?</cmsannotation> Rohan: That credit goes to Ahmed and Siddhanth, both creative geniuses. Initially, I personally thought we should stick to the name Stratton since it is well known. But now I see why Sm(all) aligns so sharply to the vision. Internally, it drives the team to leverage the power and bigness in the Sm(all). The counter intuitiveness of the name works well – Sm(all) is Strong. Sm(all) is Powerful. Sm(all) is Big. And our clients are resonating with it well too. <cmsannotation type="cmsannotation" annotationid="Q. Gozoop Group has acquired another agency during a global pandemic when the advertising industry is struggling to survive. What are some of the factors that have worked in your favour?" text="Q. Gozoop Group has acquired another agency during a global pandemic when the advertising industry is struggling to survive. What are some of the factors that have worked in your favour?">Q. Gozoop Group has acquired another agency during a global pandemic when the advertising industry is struggling to survive. What are some of the factors that have worked in your favour?</cmsannotation> Ahmed: We have always been bottom line and cash flow focused. Such a mindset works better in economic down cycles. If you look back at our history, the genesis of Gozoop lies in the deep recession of 2008. Our focus since then is to build a resilient organization that has a strong fundamental moat. It is the same resilience that enabled us to be the first advertising agency that announced performance appraisals in July last year when most agencies and networks were cutting headcounts. We had promised our team no COVID-related job losses as early as April 2020. At Gozoop, we are always building for decades and we are ok to let go of short-term gain for long-term organization building. Like all businesses, our revenues too significantly suffered last year, but keeping the long in mind we wanted to protect our people. <cmsannotation type="cmsannotation" annotationid="Q. Considering this is Gozoop Group's first acquisition during a global pandemic, did you face any kind of challenges?" text="Q. Considering this is Gozoop Group's first acquisition during a global pandemic, did you face any kind of challenges?">Q. Considering this is Gozoop Group's first acquisition during a global pandemic, did you face any kind of challenges?</cmsannotation> Ahmed: The only challenge if I can call it that is that most of our conversations happened over video calls. The funny part is Rohan and I haven’t yet met Siddhanth in person. That’s the new world for you. The pandemic has taught all of us to adapt and work with what we have. <cmsannotation type="cmsannotation" annotationid="Q. You've acquired four agencies so far. So, can you tell me what is it that you look for in your partner?" text="Q. You've acquired four agencies so far. So, can you tell me what is it that you look for in your partner?">Q. You've acquired four agencies so far. So, can you tell me what is it that you look for in your partner?</cmsannotation> Rohan: Actually Stratton marks our 5th acquisition counting the one we did in Dubai. Inorganic growth through M&amp;A has always been a part of our story starting with Red Digital in 2013, iThink in 2014, 56 Blue Lights in 2016, Hat Media in 2018, and now Stratton (2021). In all these acquisitions, we first find a value synergy. In most of these acquisitions, the founder has been active in the business and hence a value alignment is critical. For eg. Yamini (founder of 56 Blue Lights) now leads our Gozoop Dubai operations. <cmsannotation type="cmsannotation" annotationid="Q. Can you give us a sense of the deal in financial terms?" text="Q. Can you give us a sense of the deal in financial terms?">Q. Can you give us a sense of the deal in financial terms?</cmsannotation> Rohan: The deal is a mix of equity and cash with Gozoop owning a majority in the company. Like in most deals in our sector, the majority of the pay-out is based on the future cash flow performance of the business. Pre-pandemic, Stratton has Rs 2.5 crore of annual Revenues. The business did take a hit in the pandemic since it was majorly focused on the hospitality and F&amp;B sector. Today, we are well diversified amongst sectors and with the current pace of growth, we should soon outdo the pre-pandemic revenue numbers. Just in the last 2 months, we have added clients such as Cipla, Regal Shoes, ExtraMile, Nasher Miles and Aster Labs. Sm(all) is going Big! <cmsannotation type="cmsannotation" annotationid="Q. Siddhanth, what is your vision for Sm(all) now as you begin a new chapter?" text="Q. Siddhanth, what is your vision for Sm(all) now as you begin a new chapter?">Q. Siddhanth, what is your vision for Sm(all) now as you begin a new chapter?</cmsannotation> Siddhanth: Brands today don’t just need a customer base, they need a cult following that will stand with the brand, its offerings, and also its cause. Engaging and not just advertising is what I feel Sm(all) is here for. The audience today, more than ever, is aware or even uncomfortable about the fact that with every swipe or scroll there is a product advertisement that’s waiting to occupy their screens. The need for an agency/marketing partner that can help weave a narrative that goes beyond just a seasonal ad campaign, is the need of the hour in my opinion. Sm(all) envisions to be the element of change that fills this void in the segment.

Exclusive: Gozoop Group acquires Stratton Communications; acquired agency will be rebranded as Sm(all) and will focus on challenger brands

Mumbai-based pharma major <keyword id="6357157" type="CITY" weightage="80" keywordseo="Cipla">Cipla</keyword> has signed an agreement with its Sri Lankan distributor to acquire 60% stake in a new firm for $14 million (nearly Rs 85 crore). The new company will market Cipla’s products in Sri Lanka. 
	 
	The Indian company has operated in Sri Lanka for more than 15 years and is a big player in the market there. 
 A definitive agreement has been inked by Cipla (<keyword id="56022" type="COUNTRY" weightage="80" keywordseo="Mauritius">Mauritius</keyword>), a wholly owned subsidiary of the Indian firm, with its existing Sri Lankan distributor for the acquisition of 60% stake in a new company. The proposed acquisition is subject to regulatory approvals, Cipla said in a filing to the <keyword id="35140" type="CITY" weightage="80" keywordseo="BSE">BSE</keyword>. 

	Of late, Cipla has been active in acquisition as part of its global expansion strategy. 
 Last year, it completed the buyout of the <keyword id="2347306" type="UNKNOWN" weightage="80" keywordseo="South-African-pharma-company">South African pharma company</keyword> <keyword id="415177" type="UNKNOWN" weightage="80" keywordseo="Cipla-Medpro">Cipla Medpro</keyword> for Rs 2,707 crore. Last December, Cipla also acquired Croatia-based firm <keyword id="2347307" type="UNKNOWN" weightage="80" keywordseo="Celeris">Celeris</keyword>, a distributor of its products in that country.

Cipla Strikes $14 Million Deal With Its Sri Lankan Drug Distributor

<ul><li><keyword id="6397414" type="UNKNOWN" weightage="20" keywordseo="Ananth-Narayanan">Ananth Narayanan</keyword> was one of the most high profile exits from Flipkart, after it was acquired by Walmart. </li><li>Narayanan has now joined e-pharmacy startup <keyword id="3873233" type="PERSON" weightage="20" keywordseo="Medlife">Medlife</keyword>. </li><li>Medlife, which was started in 2014, reportedly does 20,000 deliveries in a day.</li></ul>Ananth Narayanan, who quit Flipkart owned Myntra after the acquisition by Walmart, has now joined Medlife as its <a href="https://www.livemint.com/companies/people/former-myntra-jabong-ceo-ananth-narayanan-joins-medlife-1564991124569.html">CEO</a>. There were rumours that Narayanan left his position as Myntra Jabong’s CEO because of his misalignment with Flipkart CEO Kalyan Krishnamurthy. Even while Narayanan was working for the company, reports said that he could join the Indian OTT platform Hotstar. However, he is now part of <keyword id="2868700" type="PERSON" weightage="20" keywordseo="online-pharmacy">online pharmacy</keyword> startup. Medlife was founded in 2014 by Tushar Kumar and Prashant Singh, and helps patients and doctors manage their files online. The company claims to perform 20,000 deliveries across India and is reportedly in talks with pharma giant Cipla for a funding round. Cipla could invest <a href="https://timesofindia.indiatimes.com/business/india-business/cipla-in-talks-to-back-e-pharmacy-medlife/articleshow/70489577.cms">₹170 crore </a>in the e-pharmacy startup. There were also reports that <a href="https://www.business-standard.com/article/companies/softbank-in-talks-to-invest-70-million-in-indian-e-pharmacy-medlife-119061301247_1.html">SoftBank</a> too was looking at investing in the startup. Bengaluru-based Medlife had also acquired its competitor <a href="https://economictimes.indiatimes.com/small-biz/startups/newsbuzz/medlife-acquires-myra-to-take-epharma-service-to-22-cities/articleshow/69193813.cms">Myra Medicines</a> earlier in May 2019, expanding its deliveries to 22 cities in India.

Former Myntra CEO Ananth Narayanan joins online pharmacy Medlife

<ul><li>The <keyword id="6354458" type="UNKNOWN" weightage="20" keywordseo="US">US</keyword> Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September.</li><li>This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials.</li></ul> The Donald Trump administration has secured nearly the entire world stock of antiviral drug <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">remdesivir</keyword> from US-based Gilead Sciences for the next three months, leaving hardly any stock of the key Covid-19 drug for the rest of the world. As a result of an agreement with the drug maker announced earlier this week, the US Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September. This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. A treatment course of remdesivir is, on average, 6.25 vials, the US Health and Human Services said. The agreement allows hospitals in the US to purchase the drug in amounts allocated by HHS and state health departments. Hospitals in the US will receive the product shipped by AmerisourceBergen and will pay no more than Gilead's Wholesale Acquisition Price (WAC), which amounts to approximately $3,200 per treatment course. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," US Health and Human Services Secretary Alex Azar said in a statement. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people." Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. To expand supply of remdesivir, Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan The agreements allow the companies -- Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. -- to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access. The regulatory approval status of remdesivir varies by country, and the distribution of remdesivir within each country is subject to local laws and regulations. Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding Covid-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier.

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

The year 2013 witnessed a great deal of volatility, with the <keyword id="6354813" type="COMPANY" weightage="40" keywordseo="nifty">Nifty</keyword> and the <keyword id="6484188" type="CITY" weightage="40" keywordseo="Sensex">Sensex</keyword> surging to new highs. Nevertheless, three out of five Nifty 50 <keyword id="6354298" type="ORGANIZATION" weightage="40" keywordseo="stocks">stocks</keyword> remained laggards, including a number of high-profile companies. 
 This year might have been forgettable for them, but these heavyweights are likely to do better in 2014, not just because of their vast potential but also due to favourable changes in the <keyword id="34412" type="ORGANIZATION" weightage="40" keywordseo="economy">economy</keyword>. ET Intelligence Group lists the companies that are likely to lead the Nifty rally in 2014 and why. 
 
<keyword id="6355199" type="CITY" weightage="40" keywordseo="Reliance-Industries">Reliance Industries</keyword> 
 
After underperforming the Nifty for five consecutive years, Reliance Industries has barely matched the index’s performance in 2013 so far, but 2014 is likely to be better. 
 
Reliance has embarked on a high capital expenditure programme, investing Rs 1,50,000 crore in three years in expanding petrochemical and polymer capacities, improving efficiencies at its refineries and increasing its dwindling gas output. 
 
 
 
Thus, FY13-FY16 is likely to be a phase of high earnings growth for the company, supporting stock outperformance. There are some risks, though. The company is fighting against penalties proposed by the petroleum ministry, while the outlook for the refining industry is clouded, with margins likely to come under pressure in 2014. Nevertheless, the company’s strong balance sheet should ensure a robust performance for its shares once the risks subside. 
 
Sesa Sterlite 
 
The government has endorsed the sale of residual stakes in its two group companies – Hindustan Zinc and Balco – through auction. This will allow Sesa Sterlite, which already holds more than 63% of HZL, to buy 25-100% of the government stake. Following this, HZL would be either merged with Sesa Sterlite or delisted. This would give Sesa Sterlite access to more than Rs 20,000 in cash with HZL and put the company in a position to bring down its debt. 
 
Also, the overall volumes of the companies across businesses – iron, copper, zinc, and oil and gas – are likely to pick up in 2014. The aluminium business could face some pressure due to falling prices. Growth in volumes and strengthening of the balance sheet will lead to re-rating of the stock, which is currently trading at a significant discount to its global peers BHP and Rio Tinto. FY15 EV/EBIDTA for Sesa Sterlite is 4.9, while it’s 6.2 and 6.6 for BHP and Rio, respectively. 
 
<keyword id="6653" type="CITY" weightage="40" keywordseo="ICICI-bank">ICICI Bank</keyword> 
 
Focus on the retail segment, a large branch network and steady loan growth may lead to consistent profit growth in the next few quarters. The bank has posted a 20% y-o-y growth in net profit in the last 12 quarters. Current and <keyword id="25450" type="UNKNOWN" weightage="40" keywordseo="savings">savings</keyword> accounts (CASA) as a percentage of total deposits improved to 43.3% in the September quarter as against 39% in the June quarter. This is among the highest among the private sector banks. 
 
Gross NPAs as of the September quarter stood at 3.08%, which is reasonable considering the macro environment. At current market prices, the stock is trading at a price-to-book value of 1.8. This is lower than peers such as HDFC Bank and Kotak Bank, which are trading at 4.5 and 3.5. Over the last few years, the stock was trading at a discount to its peers due to higher exposure to stressed assets. However, sustained profit growth in next few quarters may lead to a lower valuation gap. 
 
Ultratech Cement 
 
UltraTech Cement, being the largest company in the sector with a pan-India presence, stands to gain from the expected improvement in construction in 2014. With the acquisition of JP Associates’ Gujarat plant this year, the company’s cement capacity stands at 63 million tonnes, almost 16.8% of total domestic capacity. 
 
UltraTech Cement has been selectively expanding its capacity, which has strong long-term benefits. Cement prices are currently under pressure. In the September quarter, all-India cement prices traded at Rs 299 per 50-kg bag, up 2% from the year earlier. Once demand improves next year with the clearing of infrastructure projects, UltraTech would be one of the few large cement companies to gain. In the coming year, analysts expect cement demand to grow at 7-8%. This should improve earnings at UltraTech, which also has a light balance sheet with a debt-to-equity ratio of less than 1. 
 
<div style="page-break-after: always;">
	&#xa0;</div>
<keyword id="45475" type="CITY" weightage="40" keywordseo="Larsen-Toubro">Larsen &amp; Toubro</keyword> 
 
 
 
If there is one company that has succeeded relatively well in defying the slump in the engineering and capital goods sectors over the past few quarters, it is Larsen &amp; Toubro. The company’s increasing focus on internationalisation has helped it partly offset the slump in the domestic economy. The company had an order book of Rs 1.76 lakh crore at the end of the September quarter or close to three years of revenue. 
 
The ratio of international to domestic orders moved up from 10:90 in 
FY13 to 15:85 at the end of September. This puts pressure on operating profit margin, which at 10.2% for the trailing 12 months was 87 bps below the comparable period. An increase in domestic investment activity could ease out some stress on the margins going forward. In the event of a pick up in the investment economy in second half of 2014, it is likely to be one of the biggest beneficiaries and that will invariably boost its share price. 
 
PowerGrid 
 
PowerGrid has underperformed the broader index due to the overhang of the dilution through the recent follow-on public offer. However, PowerGrid may now not need any further equity for at least next three to four years. Under the 12th Five-Year Plan, the company has a capex target of Rs 1.1 lakh crore. 
 
In the past, the company has consistently met its execution target, which led to a compounded annual growth rate of 24% in net profit in the last five years. Given the track record on execution and the healthy capex target, profit growth may continue to remain healthy in the future. Going ahead, with concerns over equity dilution subsiding, the stock may be driven by fundamentals. 
 
Cipla 
 
Cipla, one of India’s biggest drug makers, has been through a transition phase in 2013. This has included the induction of new senior managers, changes in <keyword id="383688" type="UNKNOWN" weightage="40" keywordseo="business-strategy">business strategy</keyword> and the restructuring of various business segments. The company is now setting up front ends in the developed markets of the US and Europe with an intention to launch its own products there. It is also investing in R&amp;D to build a pipeline of products for launch. 
 
This increased initial investment has squeezed margins in recent quarters in the expectation of more sustainable growth in the future. As product approvals pick up and products are launched, the company is likely to see the fruits of this strategy in 2014. It’s likely to emerge as an outperformer in its sector by the second half of 2014.

You Searched For "cipla acquisition" and got 9 results

Cipla to acquire 21.85 pc stake in GoApptiv

PTI

Top stocks to watch — RIL, Airtel, Vodafone-Idea, Infosys, Wipro, Shalby, Cipla, and others

Navdeep Yadav

Top stock movers — RIL, Granules, TCS, Cipla, Advanced Enzyme Tech, Tata Consumer, and more

Navdeep Yadav

Cipla acquires 4 nutrition brands from Wanbury

PTI

Exclusive: Gozoop Group acquires Stratton Communications; acquired agency will be rebranded as Sm(all) and will focus on challenger brands

Karuna Sharma

Cipla Strikes $14 Million Deal With Its Sri Lankan Drug Distributor

BI India Bureau

Former Myntra CEO Ananth Narayanan joins online pharmacy Medlife

Sanchita Dash

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

IANS

These Are The 7 Nifty Stars To Look Out For In 2014

Economic Times

Popular Keywords

Buying Guides